IBD Evidence

Grein

Hvat veldur IBD? Erviligleiki, umhvørvi og vaksandi tal

Uppdatert 4 min lesing 60 tilvísingar

Tráður endoskopiskur snara brúktur til ovur gastrointestinal og kolonic polypektomi
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

Hvørki arvafrøði ella umhvørvi eina og einsamalla frágreiðir bólgutarmasjúku. Arvafrøðin sigur tær, hvør er móttakiligur; faraldsfrøðin sigur tær, at móttakiligleiki eina og einsamallur ikki kann vera heilu søguna, tí heimsútbreiðslan av sjúkuni hevur broytst ov skjótt fyri, at genir kunnu frágreiða tað.

Hvat arvafrøðin í roynd og veru vísir

Heimsbreiðar assosiatiónskanningar (GWAS) hava eyðmerkt ein munandi tal av loci, sum eru knýtt at móttakiligleika fyri IBD. Ein meta-analysa av assosiatiónsdátum eyðmerkti 38 móttakiligleika-loci og undirstrikaði arvafrøðiligan váða, sum er felags tvørturum fólkasløgum, og, serliga áhugavert, partvís felags við øðrum ónæmis-miðlaðum sjúkum [25]. Ein sundurskild heimsbreið assosiatiónskanning bendi á ónæmisaktivering av fleiri integrin-genum serliga [24] — ein mekanistiskt áhugaverdur úrslit, tí integrin-blokkerandi heilivágir (bólkin av anti-integrin biologiskum heilivágum, sum er umrøddur á okkara viðgerðarsíðu) virka við at avbróta akkurát tann leukocyt-flutningsvegin, sum hesi genir sita í.

Tann praktiska niðurstøðan frá arvafrøðini er trongari enn fólk vænta. IBD er ikki ein einki-gen, Mendel-arvað sjúka — hon er polygen, við nógvum loci, sum hvør fyri seg bíðroga eina lítla partin av váðanum. At hava ein fyrsta-grads skyldfólk við IBD hækkar váðan omanfyri tað almenna fólkasetrið, men tann stóra meiriluturin av fólki, sum bera IBD-tengdar arvafrøðiligar variantar, fáa aldrin sjúkuna. Arvafrøði setir eina móttakiligleika-treskul; okkurt annað avger, um henda treskulin verður fyribrotin.

Hví arvafrøði ikki kann vera heilu søguna

Ta arvafrøðiliga skipanin hjá einum fólkasløgum broytist ikki um nøkur áratíggju. Tann heimsbreiða nýgongdin av IBD hevur. Ein greining frá 2025 í Nature fylgir nýgongdini av IBD gjøgnum tað, sum hon nevnir faraldsfrøðiligar stig — lág nýgongd, ein flýtingarfasa har nýgongd hækkar stórliga, síðani ein samansetingar-prevalens-javnvágsfasa har nýgongd flatnar av, men talið av fólki, sum liva við sjúkuni, heldur fram at hækka, tí hon er krónisk [35]. Øki, sum í dag eru nýindustrialiserandi, ganga ígjøgnum ta somu flýtingarfasu, sum Vestur-Evropa og Norður-Amerika gingu ígjøgnum um tjúgunda øldina.

Hetta mynstrið varð dokumenterað fyrr í eini skipaðari yvirlitsrannsókn av fólkasløg-grundaðum kanningum um heimsbreiða nýgongd og prevalens [23], og ein víðari yvirlitsgrein, sum serliga viðger faraldsfrøði tvørtur allar aldursbólkar í tíðarskeiðnum við framkomnari viðgerð, staðsetur tað núverandi heimsbiletið [33]. Ein skipað yvirlitsrannsókn, sum leggur dent á IBD, sum byrjar í barnaári, fann sama flýtandi tendens serliga hjá børnum og ungdómum [15], og sjúkrahústeigingartendensir um sama tíðarskeið vórðu lýstir í eini víðari skipaðari yvirlitsrannsókn við tíðarligum greiningum [7].

Eitt landafrøðiligt og tíðarligt mynstur, sum fylgir industrialisering heldur enn arvafrøðiligan skriða, er tann sterkasta til taks røksemdin fyri, at okkurt um, hvussu eitt fólkasløg livir — ikki bara hvussu tað verður føtt — ger ein munandi part av tí orsakandi arbeiðnum.

Umhvørviskandidatarnir

Ein regnhlívar-yvirlitsrannsókn av meta-analysum kannaði umhvørvis-váðafaktorar fyri IBD beinleiðis, og savnaði sannprógving frá nógvum einstøkum útsetingar-kanningum í eina samandráttar [20]. Ta ærliga samandráttin av hesi lithteratúrini er, at fleiri kandidatar hava stuðlandi sannprógving av ymiskum styrki, og eingin er víst at vera nóg mikið eina og einsamallur — samsvarandi einari sjúku, sum sannlíkiliga krevur, at ein arvafrøðiliga móttakiligur einstaklingur møtir eini serligari samansetingum av útsetingum.

Tann eina virðið: hvussu pørturnir passa saman

FaktorbólkurHvat er staðfestHvat er ikki
Arvafrøðiligur móttakiligleikiFleiri tólvtir av bíðrogandi loci eru eyðmerktir; váði bólkast í ættum og deilir mekanismar við aðrar ónæmissjúkurEingin einstakur gen er neyðugur ella nóg mikið; flest arvafrøðiliga móttakilig fólk fáa aldrin IBD
Landafrøðiligt/tíðarligt mynsturNýgongd hækkar stórliga, tá øki industrialisera, og flatnar so av, meðan prevalens heldur fram at hækkaMynstrið vísir, at umhvørvi hevur týdning; tað eyðmerkir ikki sjálvt, hvør útseting hevur mest týdning
Einstakar umhvørvisútsetingarEin regnhlívar-yvirlitsrannsókn hevur savnað útsetingar-lithteratúrin tvørtur nógvar kandidat-faktorarEingin einstakur umhvørvisfaktor er staðfestur sum neyðugur ella nóg mikið eina og einsamallur
SamspæliðSannlíkiligt og samsvarandi við heildar-dátumynstrið: móttakiligleiki plus útsetingIkki beinleiðis mátanligt við núverandi kanningarsnið á einstaklingsstøði

Hví hetta hevur týdning í praksis

Einki av hesum broytir viðgerðina. Tað eyðmerkir ikki eina matvøru at forðast, eina lívsstílsbroyting, sum er tryggja fyri at forða uppgloppanum, ella eina roynd, sum spáir einstaklingsváðan við nýtiligari nágreini. Tað, sum tað frágreiðir, eru tvey lutir, sjúklingar ofta fáa ósamsvarandi upplýsingar um: at IBD ikki er "orsakað" av mataræði ella stressi í nøkrum einfaldum týdningi (arvafrøði og umhvørvisbroytingar á fólkasløgsstøði gera nógv meiri av tí orsakandi arbeiðnum enn dagligar valmøguleikar), og at hon eisini ikki er reint arvafrøðilig óheppi (ta hækkandi nýgongdin í nýindustrialiserandi økjum útilokar tað eina og einsamalt). Báðar hesar umrammingarnar minka ofta um ta skuld, sjúklingar fráboða kring "hvat gjørdi eg fyri at orsaka hetta" — ein spurningur, sum sannprógvingargrundarlagið í roynd og veru ikki stuðlar at spyrja um nakað einstakt atferð.

Vanlig spurningar

Er IBD arvaligt? Fáa mínir børn tað?
Váðin er hækkaður hjá fyrsta-grads skyldfólki hjá onkrum við IBD, men tann stóra meiriluturin av skyldfólki fáa hann aldrin. Tað er eitt móttakiligleika-genmynstur, ikki ein Mendel-arvað sjúka.
Orsakaði okkurt, eg át ella gjørdi, IBD hjá mær?
Eingin einstakur mataræðis- ella lívsstílsfaktor er staðfestur sum ein nóg mikið orsøk. Sannprógvingin peikar á eina samansetingum av arvafrøðiligum móttakiligleika og umhvørvisútsetingum á fólkasløgsstøði, sum spælar seg út um mong ár, ikki ein eyðmerkiligan einstaklingsútloysara.
Hví verður IBD meira vanligt í londum, har tað áður var sjáldsamt?
Hetta fylgir industrialisering so nær, at tað er ein av teimum sterkastu røksemdunum fyri einum umhvørvisligum parti — genir broytast ikki nóg skjótt fyri at frágreiða tað, og mynstrið er nú dokumenterað tvørtur nógv øki og tíðarskeið.
Um arvur bara greiðir frá næmi, hvat er tá hin veruligi útloysarin?
Ikki staðfest við neyvd. Møguligar umhvørvisáhrivanir eru tiknar saman í “umbrella”-yvirlitskanningum, men eingin einstakur faktor er sannaður at vera neyðugur ella nøktandi — hetta er framvegis eitt opið kanningarøki heldur enn ein loyst spurningur.
Trý kamerahylki nýtt til at taka myndir av vélindanum, tunntarminum og digra tarminum
Svolgdar hylki taka myndir av partum av tunnutarmi, sum ein vanlig endoskopi ikki kann náa. Dr.HH.Krause · CC BY-SA 3.0 · Wikimedia Commons

Tengt lesing

Evidensin fyri hesa síðu Ein stakkur bar, sum vísir samansetingina av teimum 30 útgávunum, ið eru nevndar á hesi síðu, eftir rannsóknartypi. 2563meta-analysis (25)randomised trial (6)review (3)other (1)
35 útgávur, 2015–2026. Hetta er ein blanding av bæði royndum og samansetingum, sum er støðan, har frá ein áheitan um orsøkin er skilvís. Kelda: egnu tilvísingalistin á hesi síðu, niðanfyri.

Viðmerkingar

Hver einasta tilvísing niðanfyri bendir til upprunaliga peer-reviewed skjalið á PubMed ella gjøgnum DOI. Einki her er ein staðfesting fyri læknaligt ráð.

  1. Dual biologics or combination therapy with small molecules in pediatric inflammatory bowel disease: a systematic review and meta-analysis Huo BL, Zhao AL, Liu W, et al. · World journal of pediatrics : WJP · 2026 · Meta-analysis DOIPubMed 42387245
  2. Mediterranean diet in treatment of inflammatory bowel disease: A systematic review and meta-analysis Singh A, Rana U, Chandnani S, et al. · Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026 · Meta-analysis DOIPubMed 41803562
  3. Study Design Complexity and Participant Completion in Dietary Trials for Inflammatory Bowel Disease: A Systematic Review and Metaresearch Study Gregersen L, Moos C, Hikmat Z, et al. · Advances in nutrition (Bethesda, Md.) · 2026 · Systematic review DOIPubMed 41825595Full text
  4. Phenotypic Differences in Inflammatory Bowel Diseases Across Race, Ethnicity, and Geography: A Systematic Review of 237 Population-Based Studies Halim A, Ho AHY, Wanchaitanawong W, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Meta-analysis DOIPubMed 41577066
  5. Blood Bile Acids for Inflammatory Bowel Disease Diagnosis and Disease Activity Assessment: A Metabolomics Meta-Analysis Thu NQ, An VT, Dat LHB, et al. · Journal of proteome research · 2026 · Meta-analysis DOIPubMed 42695907
  6. Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis Moraes BF, Leite GAPD, Visentini LM, et al. · Journal of Crohn's & colitis · 2026 · Meta-analysis DOIPubMed 41874976
  7. The Role of Inflammation in Infant Colic-A Systematic Review and Meta-Analysis Andersen DB, Fog J, Vestergaard MV, et al. · Acta paediatrica (Oslo, Norway : 1992) · 2026 · Meta-analysis DOIPubMed 41803938Full text
  8. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  9. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  10. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  11. Pre-Illness Index-Based Dietary Patterns and Inflammatory Bowel Disease Risk: A Systematic Review and Meta-Analysis Meng F, Zhang T, Meng X, et al. · Nutrition reviews · 2025 · Meta-analysis DOIPubMed 40700526
  12. Using Diet to Treat Inflammatory Bowel Disease: A Systematic Review Gleave A, Shah A, Tahir U, et al. · The American journal of gastroenterology · 2025 · Systematic review DOIPubMed 39056556
  13. Efficacy of a Low-FODMAP Diet on the Severity of Gastrointestinal Symptoms and Quality of Life in the Treatment of Gastrointestinal Disorders-A Systematic Review of Randomized Controlled Trials Kuźmin L, Kubiak K, Lange E · Nutrients · 2025 · Systematic review DOIPubMed 40573159Full text
  14. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  15. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes Zheng T, Roda G, Zabana Y, et al. · Journal of Crohn's & colitis · 2024 · Meta-analysis DOIPubMed 37768647
  16. Acute severe ulcerative colitis trials: the past, the present and the future Honap S, Jairath V, Sands BE, et al. · Gut · 2024 · Systematic review DOIPubMed 38834296Full text
  17. Efficacy of different dietary therapy strategies in active pediatric Crohn's disease: a systematic review and network meta-analysis Ma J, Chong J, Qiu Z, et al. · PeerJ · 2024 · Meta-analysis DOIPubMed 39686992Full text
  18. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses Buie MJ, Quan J, Windsor JW, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · Meta-analysis DOIPubMed 35863682
  19. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  20. Features of paradoxical psoriasis and risk factors in inflammatory bowel disease: A systematic review and meta-analysis Croitoru DO, Brooks SG, Nathanielsz N, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Meta-analysis DOIPubMed 36912825
  21. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  22. High-Fiber Diet and Crohn's Disease: Systematic Review and Meta-Analysis Serrano Fernandez V, Seldas Palomino M, Laredo-Aguilera JA, et al. · Nutrients · 2023 · Meta-analysis DOIPubMed 37513532Full text
  23. Dietary Interventions in Ulcerative Colitis: A Systematic Review of the Evidence with Meta-Analysis Herrador-López M, Martín-Masot R, Navas-López VM · Nutrients · 2023 · Meta-analysis DOIPubMed 37836478Full text
  24. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  25. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  26. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  27. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  28. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review Kuenzig ME, Fung SG, Marderfeld L, et al. · Gastroenterology · 2022 · Systematic review DOIPubMed 34995526
  29. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  30. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease Sinopoulou V, Gordon M, Akobeng AK, et al. · The Cochrane database of systematic reviews · 2021 · Systematic review DOIPubMed 34844288Full text
  31. Systematic Review of the Effects of Oat Intake on Gastrointestinal Health Valido E, Stoyanov J, Bertolo A, et al. · The Journal of nutrition · 2021 · Systematic review DOIPubMed 34486656
  32. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  33. Incidence of SARS-CoV-2 infection in inflammatory bowel disease Lee MH, Ng CH, Chin YH, et al. · Journal of gastroenterology and hepatology · 2020 · Meta-analysis DOIPubMed 32779774Full text
  34. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  35. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses Piovani D, Danese S, Peyrin-Biroulet L, et al. · Gastroenterology · 2019 · Meta-analysis DOIPubMed 31014995
  36. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  37. ESPEN guideline: Clinical nutrition in inflammatory bowel disease Forbes A, Escher J, Hébuterne X, et al. · Clinical nutrition (Edinburgh, Scotland) · 2017 · Systematic review DOIPubMed 28131521
  38. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Ng SC, Shi HY, Hamidi N, et al. · Lancet (London, England) · 2017 · Systematic review DOIPubMed 29050646
  39. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  40. Inflammatory bowel disease and risk of stroke: A meta-analysis of cohort studies Yuan M, Zhou HY, Xiao XL, et al. · International journal of cardiology · 2016 · Meta-analysis DOIPubMed 26386936
  41. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS Menees SB, Powell C, Kurlander J, et al. · The American journal of gastroenterology · 2015 · Meta-analysis DOIPubMed 25732419
  42. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Liu JZ, van Sommeren S, Huang H, et al. · Nature genetics · 2015 · Meta-analysis DOIPubMed 26192919Full text
  43. Consumption of vegetables and fruit and the risk of inflammatory bowel disease: a meta-analysis Li F, Liu X, Wang W, et al. · European journal of gastroenterology & hepatology · 2015 · Meta-analysis DOIPubMed 25831134
  44. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis Zhou XL, Xu W, Tang XX, et al. · BMC gastroenterology · 2014 · Meta-analysis DOIPubMed 25002150Full text
  45. Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial Wellens J, Vanderstappen J, Hoekx S, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Randomised controlled trial DOIPubMed 40816342
  46. A Randomised Controlled Trial Comparing the Effects of Personalised Diet and Physical Activity Intervention Versus Usual Care on Cardiometabolic Risk Factors in Adults with Inactive Inflammatory Bowel Disease Yap JM, Wall CL, Meredith-Jones K, et al. · Nutrients · 2026 · Randomised controlled trial DOIPubMed 41829955Full text
  47. Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study Minato I, Mena P, Ricciardiello L, et al. · Molecular nutrition & food research · 2025 · Randomised controlled trial DOIPubMed 40255128Full text
  48. Effects of bromelain supplementation on disease activity and quality of life in patients with ulcerative colitis: a randomized, triple-blind, placebo-controlled study Delgarm P, Mokhtare M, Ebrahimi Daryani N, et al. · Scientific reports · 2025 · Randomised controlled trial DOIPubMed 41315628Full text
  49. Whole Food Diet Induces Remission in Children and Young Adults With Mild to Moderate Crohn's Disease and Is More Tolerable Than Exclusive Enteral Nutrition: A Randomized Controlled Trial Aharoni-Frutkoff Y, Plotkin L, Pollak D, et al. · Gastroenterology · 2025 · Randomised controlled trial DOIPubMed 40553742
  50. The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial Pasta A, Formisano E, Calabrese F, et al. · European journal of clinical investigation · 2025 · Randomised controlled trial DOIPubMed 39853756
  51. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Ferrante M, D'Haens G, Jairath V, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39581202
  52. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial Yanai H, Levine A, Hirsch A, et al. · The lancet. Gastroenterology & hepatology · 2022 · Randomised controlled trial DOIPubMed 34739863
  53. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial Cox SR, Lindsay JO, Fromentin S, et al. · Gastroenterology · 2020 · Randomised controlled trial DOIPubMed 31586453
  54. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition Svolos V, Hansen R, Nichols B, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 30550821
  55. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial Levine A, Wine E, Assa A, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 31170412
  56. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. · The New England journal of medicine · 2019 · Randomised controlled trial DOIPubMed 31553834
  57. Chronic, Noninfectious Diarrhea: A Review Singh P, Lee A, Sheth NM, et al. · JAMA · 2026 · Review DOIPubMed 41770539
  58. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies Caron B, Honap S, Peyrin-Biroulet L · Journal of Crohn's & colitis · 2024 · Review DOIPubMed 39475082Full text
  59. Mild Crohn's Disease: Definition and Management Claytor J, Kumar P, Ananthakrishnan AN, et al. · Current gastroenterology reports · 2023 · Review DOIPubMed 36753033
  60. Global evolution of inflammatory bowel disease across epidemiologic stages Hracs L, Windsor JW, Gorospe J, et al. · Nature · 2025 · Journal article DOIPubMed 40307548Full text

Henda síða varð sjálvvirkandi týdd úr enskt. Tilvísingarnar og tølini eru óbroytt. Les upprunaliga enska útgávuna um nakað lesist undarliga. Les upprunaliga enska útgávuna